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ABBREVIATIONS 
 
BAPTA-AM   -  1,2-bis-(o-Aminophenoxy) ethane-N,N,N’,N’-tetraacetic acid                           
    tetra-acetoxymethyl ester 
cDNA   -  complementary deoxyribonucleic acid  
CTRC    -  chymotrypsin C 
Del    -  deletion 
DMEM  - Dulbecco's modified Eagle's medium 
DMSO   -  dimethyl sulfoxide 
EDTA   -  ethylene diamine tetracetic acid 
FBS                            - foetal bovine serum 
FURA 2-AM              -  5-Oxazolecarboxylic acid, 2-(6-(bis(carboxymethyl)amino)-
5-(2-(2 (bis(carboxymethyl)amino)-5 
methylphenoxy)ethoxy)-2-benzofuranyl)-5-
oxazolecarboxylic acetoxymethyl ester 
HEK   -  human embryonic kidney 
HP   - hereditary pancreatitis 
mRNA  -  messenger ribonucleic acid 
MS/MS    -  tandem mass spectrometry 
PAR-2   - protease-activated receptor-2 
PCR    -  polymerase chain reaction 
PRSS1   - cationic trypsinogen (regular / bold letters – protein / gene) 
PRSS2   - anionic trypsinogen (regular / bold letters – protein / gene) 
ROI    -  region of interest 
SDS-PAGE   -  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SERCA  - sarcoplasmic reticulum Ca2+-ATPase 
SMART RACE          - Switching Mechanism At 5' end of RNA Transcript, rapid 
amplification of cDNA ends 
SPINK1  -  pancreatic secretory trypsin inhibitor 
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SUMMARY 
 
Background. Acute pancreatitis usually develops due to the blockage of the main 
pancreatic duct by a gallstone, whereas chronic pancreatitis is a series of recurring 
inflammatory attacks, where the primary cause is mostly alcoholism. Hereditary chronic 
pancreatitis is a rare form of early onset chronic pancreatitis, which accumulates in 
selected families suggesting a genetic background. These pancreatic diseases show 
variable severity in which some patients manifest a severe, highly morbid, and frequently 
lethal attack during acute inflammation, while others experience mild, self-limited attacks 
mostly during chronic inflammation. It is generally believed that the earliest events in 
acute pancreatitis occur within acinar cells and the digestive protease trypsin plays a 
fundamental pathogenetic role in the initiation of cell injury, however, the exact intraacinar 
mechanisms by which diverse etiological factors induce an attack are still unclear.  
The aims of the present investigations summarized in this thesis were to examine the role 
of trypsin and bile acids in the initiation of acute and chronic pancreatitis. We purified and 
cloned the trypsinogen isoforms from the guinea pig pancreas and characterized their 
activation properties. We analyzed the gene encoding the trypsin-degrading enzyme 
chymotrypsin C (CTRC) in German subjects with idiopathic or hereditary chronic 
pancreatitis and determined the activity and/or secretion abnormalities of the most frequent 
variants. Thirdly, we characterised the effect of trypsin and bile acids on the intracellular 
calcium signalling of guinea pig pancreatic duct epithelial cells.    
Methods. Guinea pig trypsinogens from pancreatic homogenates were isolated by ecotin-
affinity chromatography, followed by cation-exchange chromatography. Complementary 
DNAs for pre-trypsinogens were cloned from total RNA after reverse transcription and 
PCR-amplification, activation of trypsinogens was tested with enteropeptidase, cathepsin B 
and trypsin.  
We carried out direct DNA sequencing of the CTRC gene in 2804 control and 901 affected 
individuals with chronic pancreatitis. Then, plasmids carrying the wild-type and the most 
frequent variants of CTRC were constructed by overlap extension PCR mutagenesis. The 
plasmids were expressed in human embryonic kidney (HEK) cells and AR42J rat 
pancreatic acinar cells through transient transfection. Chymotrypsin C activity assay and 
potein blotting were performed from the media and cell extract of the transfected samples 
to determine possible secretion and/or activity changes of the variants.  
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Pancreatic ducts were isolated from guinea pig, after overnight culture at 37 oC, then the 
ducts were loaded with the calcium sensitive fluorescent dye FURA-2. Intracellular 
calcium measurements were performed using the CellR Imaging System. 
Results and discussion. Purification of trypsinogens yielded a single peak with an N-
terminal amino-acid sequence of LPIDD. Cloning of pre-trypsinogen cDNAs revealed two 
distinct but nearly identical isoforms. At the amino acid level, the only difference between 
the two isoforms is an Ala/Ser change at position 15 within the signal peptide. Thus, both 
cDNA variants give rise to the same mature trypsinogen upon secretion. Guinea pig 
trypsinogen is readily activated by enteropeptidase and cathepsin B, but exhibits essentially 
no autoactivation, under conditions where human cationic and anionic trypsinogens rapidly 
autoactivate. The observations suggest that multiple trypsinogen isoforms and their ability 
to autoactivate are not required universally for normal digestive physiology in mammals. 
Furthermore, the inability of guinea pig trypsinogen to undergo autoactivation suggests 
that this species might be more resistant to pancreatitis than humans, where increased 
autoactivation of cationic trypsinogen mutants has been linked to hereditary pancreatitis.  
During the mutation screening of the chymotrypsin C gene, we found two alterations, 
p.R254W (arginine > tryptophan) and p.K247_R254del (deletion of 8 amino acids), which 
were significantly over-represented in the pancreatitis group and were present in 30/901 
(3.3%) affected individuals but only in 21/2,804 (0.7%) controls. A replication study 
identified these two variants in 10/348 (2.9%) individuals with alcoholic chronic 
pancreatitis but only in 3/432 (0.7%) subjects with alcoholic liver disease. Chymotrypsin C 
variants were also found in 10/71 (14.1%) Indian subjects with tropical pancreatitis but 
only in 1/84 (1.2%) control. Functional analysis of the chymotrypsin C variants revealed 
impaired activity and/or reduced secretion. The results indicate that loss-of-function 
alterations in chymotrypsin C predispose to pancreatitis by diminishing its protective 
trypsin-degrading activity. In summary, the genetic and functional data of our study 
identifies chymotrypsin C as a new pancreatitis-associated gene.  
Experiments on the effects of trypsin on guinea pig pancreatic ducts showed that trypsin 
dose-dependently activated Ca2+-signalling from the basolateral membrane of the cells and 
the protease-activated receptor-2 (PAR-2) agonist mimicked the effect. Soybean trypsin 
inhibitor and the calcium chelator BAPTA-AM totally blocked the basolateral effect of 
trypsin on intracellular calcium concentration ([Ca2+]i). Trypsin also evoked Ca2+ 
signalling in a Ca2+ free external solution, suggesting that Ca2+ is presumably released 
from intracellular stores. Luminal administration of trypsin also elevated [Ca2+]i suggesting 
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the luminal localization of the PAR-2. Immunohistochemical analyses confirmed that the 
PAR-2 is expressed on the luminal membrane of intralobular but not interlobular ducts.  
Examinations on the effects of bile acids on primary pancreatic ducts revealed that both 
basolateral and luminal administration of high doses of chenodeoxycholate and 
glycochenodeoxycholate triggered calcium responses in guinea pig pancreatic duct 
epithelial cells, while only the low dose of chenodeoxycholate and not 
glycochenodeoxycholate caused calcium signals in the cells. Neither the parasympatholytic 
atropine nor removal of calcium from the extracellular standard HEPES solution had any 
effect on the elevation of [Ca2+]i evoked by luminal administration of low dose of 
chenodeoxycholate. However, the calcium-chelator, BAPTA-AM, and the inositol 
triphosphate (IP3) receptor inhibitor caffeine totally blocked the calcium response. Both the 
IP3 receptor inhibitor xestospongin C and the phospholipase C inhibitor U73122  blocked 
the intracellular calcium response of low doses of chenodeoxycholate and slightly inhibited 
the [Ca2+]i  elevation of high doses of chenodeoxycholate of basolateral and luminal 
administration. 
These experiments on the effects of trypsin and bile acids on pancreatic ducts suggests that  
PAR-2 may be the target by which pancreatic duct cells are activated by trypsin at the early 
stages of acute pancreatitis. During pathological conditions, when a bile stone impacts in 
the ampulla of Vater resulting in bile reflux into the pancreatic ductal system, bile acids 
can also activate pancreatic ductal epithelial cells through intracellular calcium signalling 
mechanisms and the activated cells might play an important role during the inflammation 
of pancreatic tissue. 
 
1. INTRODUCTION 
 
1.1 The role of trypsinogen and chymotrypsinogen in acute 
pancreatitis 
 
 Trypsinogen is the most abundant digestive protease of the pancreas which, under 
normal conditions, becomes active only when it is secreted into the duodenum. However, 
numerous studies have concluded that premature activation of intraacinar trypsinogen is a 
critical initiating factor that leads to the injury of acini, cell death and finally to acute 
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The human pancreas secretes three isoforms of trypsinogen, encoded by the 
protease, serine (PRSS) genes 1, 2 and 3. On the basis of their relative electrophoretic 
mobility, the three trypsinogen species are commonly referred to as cationic trypsinogen 
(product of PRSS1), anionic trypsinogen (product of PRSS2), and mesotrypsinogen 
(product of PRSS3) [2]. While individual variations definitely exist, normally the cationic 
isoform constitutes about 2/3 of the total trypsinogen content, and anionic trypsinogen 
makes up approximately 1/3 [3, 4, 5]. Mesotrypsinogen is a minor species, accounting for 
less than 5% of trypsinogens in human pancreatic juice [6, 7]. Human trypsinogens are 
synthesized as preproenzymes with 247 amino acid containing a signal peptide of 15 
residues, followed by the above mentioned trypsinogen activation peptide. The signal 
peptide is removed upon entry into the endoplasmic reticulum lumen and the proenzymes 
(also called zymogens) are packed into zymogen granules and eventually secreted into the 
pancreatic juice. The intestinal endopeptidase, enterokinase, produced by enterocytes [8], 
converts trypsinogen to trypsin by release of the N-terminal octapeptide (trypsinogen 
activation peptide). 
 Chymotrypsinogen is the second proenzyme in the cascade of pancreatic protease 
activation and can be activated by trypsin [9]. The striking similarity between 
chymotrypsinogen and trypsinogen is well known, they have highly homologous primary 
and tertiary structures [10], such as the number and composition of amino acids. The main 
difference between the two enzymes lies in their substrate specificity. While trypsin 
hydrolyses the polypeptide chain at the lysyl and arginyl bonds, chymotrypsin selectively 
cleaves peptide bonds formed by aromatic residues, like phenylalanine, tyrosine and 
tryptophan [11, 12]. The major chymotrypsin isoform in the human pancreas is 
chymotrypsin B, which is expressed as two nearly identical isoforms (CTRB1 and CTRB2) 
[13], the third minor isoform is chymotrypsin C. Chymotrypsin C was first isolated from 
pig pancreas and was shown to exhibit protease activity distinct from the bovine or porcine 
chymotrypsin A or the bovine chymotrypsin B [14]. Recently, chymotrypsin C-mediated 
acceleration of trypsinogen activation has been described and compared to the 
autoactivation of chymotrypsin C-cleaved normal cationic trypsinogen, the pancreatitis-
associated mutation A16V in cationic trypsinogen increased the rate of autoactivation in 
vitro. Thus, the chymotrypsin C-mediated stimulation of autoactivation plays a role in the 
pathogenesis of human pancreatitis [15]. Novel findings show that chymotrypsin C has 
been identified as a key regulator of activation and degradation of cationic trypsin. Thus, in 
the high Ca2+ environment of the duodenum, chymotrypsin C facilitates trypsinogen 
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activation, whereas in the lower intestines, chymotrypsin C promotes trypsin degradation 
as a function of decreasing luminal Ca2+ concentrations [16].     
At present, it is widely accepted that the premature activation of digestive enzymes 
within the pancreatic acinar cells is a critical initiating event leading to autodigestion of 
pancreas [17, 18, 19, 20]. Inappropriate activation of trypsinogen can take place in the 
zymogen granules of acinar cells [21] but the exact process of activation is still 
controversial. There are several hypotheses of intra-acinar trypsinogen activation. 
According to the trypsinogen autoactivation theory, trypsin-induced trypsinogen activation 
or autoactivation is the triggering event that occurs in the acini [22]. The colocalization 
hypothesis describes that the lysosomal cysteine protease cathepsin B plays an essential 
role in the mechanisms of trypsinogen activation as cathepsin B during the inappropriate 
colocalization of lysosomes with zymogen granules may activate trypsinogen, as it was 
proved in in vitro studies [23, 24]. Prolonged high concentration of calcium in acinar cells 
might also be an important initial factor in disrupted cell signalling that leads to cellular 
injury. Pancreatic secretory trypsin inhibitor, or in other words, serine protease inhibitor, 
Kazal type I (SPINK1) is also present in secretory granules of acinar cells that is thought to 
be a specific inactivation factor of intrapancreatic trypsin activity. Defect of this inhibitor 
can result in the imbalance of trypsinogen activation and trypsin inactivation that leads to 
pathological conditions. When more than about 10-20% of trypsinogen is activated 
intracellularly, the inhibitory mechanism is no longer effective, cellular injury occurs, 
which leads to the death of acinar cells and finally to acute pancreatitis [25, 26].  
Comfort and Steinberg were first to recognize that chronic pancreatitis may 
accumulate in selected families suggesting a genetic background [27]. Thereafter, 
hereditary chronic pancreatitis was defined as an autosomal dominant disease with a 
penetrance of approximately 80%. In the past decade, intense research has been performed 
to identify mutations in trypsinogen genes that could be associated with pancreatitis. To 
date, 22 PRSS1 gene variants have been found, which are, interestingly, located in the N-
terminal part of the protein. The three most prevalent mutations according to frequency of 
occurrence are R122H (approximately 70%), N29I (approximately 25%), and A16V 
(approximately 4%). The R122H mutation was the first identified cationic trypsinogen 
variant [28]. It shows increased trypsinogen autoactivation and also increased trypsin 
stability because the mutation decreases autolysis as Arg122 is an important autolytic site. 
The N29I was found to have normal autolysis but enhanced autoactivation, which led to 
the conclusion that increased autoactivation is the common pathogenic mechanism of 
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hereditary pancreatitis-associated PRSS1 mutations [29]. The third most frequent variant, 
A16V, which alters the N-terminal amino acid of trypsinogen, has appeared to be an 
exception, as in a recent study, the A16V mutant failed to exhibit increased autoactivation 
[30]. Interestingly, the genetic variants of PRSS2 or PRSS3 have not been described in 
association with chronic pancreatitis [31, 32], although, a recent paper has proved that a 
PRSS2 variant, G191R, which was surprisingly over-represented in the control group, 
results in a degradation-sensitive protein that protect against chronic pancreatitis [33]. 
 
1.2 The effects of bile acids and trypsin on pancreatic ductal 
epithelium 
 
Exposure of the pancreas to bile acids is considered to be one of the possible causes 
of acute pancreatitis. Since the pancreatic and bile ducts share a common outflow into the 
duodenum, the obstruction of the ampulla of Vater may cause bile to penetrate into the 
pancreatic duct, exposing the pancreas to bile acids [34]. Although the bile can reach both 
acinar and ductal cells during biliary pancreatitis, much more research has been done on 
acinar cells. Bile acids have been shown to induce Ca2+ signalling in pancreatic acinar cells 
via an IP3-dependent mobilization of intracellular Ca2+ and an inhibition of SERCA-
(Sarcoplasmic Reticulum Ca2+-ATPase) dependent Ca2+ reloading into intracellular pools 
[35]. The elevated intracellular Ca2+ concentration can lead to enzyme activation [36] 
and/or cell death [37], and result in severe acute necrotizing pancreatitis. These data 
suggest that Ca2+ toxicity could be an important factor contributing to bile acid-induced 
cellular damage in both the acinar and also the ductal epithelial cells. 
It has been shown, that retrograde injection of Na-taurocholate into the rat 
pancreatic duct induces fluid hypersecretion and decreases protein output in the initial 
phase of acute pancreatitis [38]. We believe that the pancreatic ductal epithelium is at least 
in part involved in the hypersecretory effect of bile acids, which may represent a defence 
mechanism against bile acids in order to avoid pancreatic injury. The aim of the third part 
of the thesis was to characterize the effects of bile acids and trypsin on the intracellular 
Ca2+ signalling of pancreatic duct epithelial cells. We performed our experiments on intact 
isolated guinea pig pancreatic ducts, because the guinea pig pancreas secretes a juice 
containing ~140mM NaHCO3 as does the human gland [39]. 
Protease-activated receptors (PARs) are a family of G-protein coupled receptors 
activated by proteolysis [40]. Specific serine proteases cleave the extracellular portion of 
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the receptor protein to generate a tethered ligand. This tethered ligand activates the 
receptor triggering intracellular signalling. PAR-2 is specifically activated by trypsin and is 
localized along the pancreatic ductal systems as well as the gastrointestinal tract, kidney, 
liver, bronchial tree, prostate, ovary, brain and eye [41]. Furthermore, PAR-2 receptor has 
been identified in acinar cells and linked to the release of amylase [42]. Nguyen et al. 
detected PAR-2 in dog pancreatic duct cells and found that the activation of PAR-2 led to 
increased Ca2+-activated Cl- and K+ conductances, linking the activation of the receptor 
with pancreatic secretory function [43]. They localized the receptor to the basolateral 
membrane by immunofluorescent staining of the tissue. Alvarez et al. described the 
presence of PAR-2 in bovine main pancreatic ducts but they revealed the inhibitory effects 
of trypsin on bicarbonate secretion and localized the receptor to the apical membrane [44]. 
Detection of PAR-2 in human pancreatic ductal adenocarcinoma cells has been described 
by immunoblotting [45]. These controversial studies have led us to examine the function of 
PAR-2 receptors in guinea pig pancreatic ducts.  
 
2. MATERIALS AND METHODS 
2.1 MATERIALS 
 
Whole pancreata from Abyssinian guinea pigs were purchased from Rockland 
Immunochemicals (Gilbertsville, PA). The pancreata were flash frozen in liquid nitrogen, 
shipped on dry ice and stored at -80 oC. RNAqueousTM Phenol-free total RNA Isolation kit 
was from Ambion Inc. (Austin, TX, USA), SMARTTM RACE cDNA Amplification Kit 
from Clontech Laboratories Inc. (Mountain View, CA), Zero Blunt TOPO PCR Cloning 
Kit from Invitrogen Corp. (Carlsbad, CA, USA) and N-CBZ-Gly-Pro-Arg-p-nitroanilide 
from Sigma-Aldrich (St. Louis, MO, USA). Recombinant human pro-enteropeptidase was 
from R&D Systems (Minneapolis, MN, USA). Human recombinant cathepsin B was a 
generous gift from Paul M. Steed (Research Department, Novartis Pharmaceuticals, 
Summit, New Jersey, USA). 
The compositions of the solutions used for measurements of intracellular calcium 
concentration are shown in Table 1. Chromatographically pure collagenase was purchased 
from Worthington (Lakewood, NJ, USA). CellTak was obtained from Becton Dickinson 
Labware (Bedford, MA, USA). 2-(6-(bis(carboxymethyl)amino)-5-(2-(2-
(bis(carboxymethyl)amino)-5-methylphenoxy)ethoxy)-2-benzofuranyl)-5-
 12 
oxazolecarboxylic acetoxymethyl ester (FURA 2-AM), and 1,2-bis(o-
aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA-AM) were from Molecular 
Probes Inc. (Eugene, OR, USA). Coomassie Brilliant Blue R-250 was from Pierce 
Biotechnology, Inc. (Rockford, IL, USA) Trypsin, bile acids and all other chemicals were 
obtained from Sigma-Aldrich (Budapest, Hungary). BAPTA-AM was disolved in dimethyl 
sulfoxide (DMSO), FURA 2-AM in DMSO containing 20 % pluronic acid.  
 
 
Standard 
HEPES 
Standard 
HCO3- 
Ca2+-free 
HEPES 
NaCl 130 115 132 
KCl 5 5 5 
MgCl2 1 1 1 
CaCl2 1 1  
Na-HEPES 10  10 
Glucose 10 10 10 
NaHCO3  10  
            Values are concentrations in mM. 
 
Table 1. Composition of solutions used for measurements of intracellular calcium concentration. 
 
2.2 METHODS 
 
2.2.1 Purification of trypsinogen. Guinea pig pancreatic tissue (5 g) was homogenized 
in 0.1 M Tris-HCl, pH 8.0 using a rotor-stator tissue homogenizer (T 25, IKA Works, 
USA) at 11,000 – 13,000 rpm and the homogenate was centrifuged for 8 min at 13,000 
rpm, at 4 oC. The supernatant was further clarified by a second round of centrifugation, and 
then loaded onto a 2 mL ecotin-affinity column [46]. The column was washed with 20 mM 
Tris–HCl (pH 8.0), 0.2 M NaCl and elution was performed with 50 mM HCl. The ecotin-
eluate (~1 mg protein in 3-4 mL volume) was directly loaded onto a Mono S HR 5/5 strong 
cation-exchange column equilibrated with 20 mM Na-acetate (pH 5.0). The Mono S 
column was developed with a linear gradient of 0-0.5 M NaCl. Concentrations of guinea 
pig trypsinogen preparations were estimated from UV absorbance at 280 nm, using a 
theoretical extinction coefficient of 37,650 M-1 cm-1 
(http://ca.expasy.org/tools/protparam.html). 
2.2.2. MS/MS peptide sequencing of purified guinea pig trypsinogen. To obtain 
independent sequence information from the purified guinea pig trypsinogen, a sample was 
subjected to tandem MS (mass spectrometric) peptide sequencing by ProtTech Inc, 
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Eagleville, PA, USA. After electrophoresis on a 15 % SDS-PAGE, the trypsinogen band 
was excised and digested in-gel with sequencing grade modified porcine trypsin (Promega 
Corp, Madison, WI, USA). The resulting mixture was then analyzed by LC (liquid 
chromatography)-MS/MS (ProtTech, Inc, Eagleville, PA, USA). 
2.2.3. Complementary DNA cloning. Total RNA isolation was performed from 30 mg 
homogenized guinea pig pancreas by the RNAqueousTM kit. Phenol-free total RNA 
Isolation kit modified with an additional phenol-chloroform extraction. First-strand cDNA 
was synthesized using the SMARTTM RACE cDNA Amplification Kit with 2 µg RNA. For 
the 5' RACE reaction, first-strand synthesis was primed with an oligo(dT) primer. The 
reverse transcriptase used in the reaction exhibits terminal transferase activity and adds a 
series of dC residues to the 3' end of the cDNA. An oligonucleotide (SMART IIA) present 
in the reaction mixture anneals to the dC stretch and serves as template for further 
extension of the cDNA. The end result of the reaction is a full length cDNA with an 
additional SMART sequence at the 5' end. For the 3' RACE, the mRNA is reverse 
transcribed with an oligo(dT) primer which anneals to the polyA tail and also incorporates 
the SMART sequence at its 5' end. Guinea pig trypsinogen cDNA was PCR-amplified in 2 
reactions from the first-strand 5' and 3' RACE cDNAs using a gene-specific primer and a 
Universal primer that annealed against the SMART sequence incorporated into the first-
strand cDNA either at the 5' or 3' ends. The gene specific GP1 primers annealed with 
relatively low stringency to the region around the conserved catalytic Ser200 (see Fig 2); 
the GP1 sense primer (5`-TGT CAG GGA GAC TCT GGT GGC CCA GTT GTC TGC-
3`) corresponded to codons 196-206, and the GP1 antisense primer (5`-GCA GAC AAC 
TGG GCC ACC AGA GTC TCC CTG-3') corresponded to codons 197-206 (Fig 2). These 
primers were previously designed against the corresponding region of the Bothrops 
jararaca trypsinogen (GenBank #AF190273) and used successfully in other cloning 
projects in our laboratory. PCR products were purified and directly subcloned into the 
pCR-Blunt II-TOPO vector using the Zero Blunt TOPO PCR Cloning Kit (Invitrogen). 
Fifteen clones from the 5' RACE reaction and 3 clones from the 3' RACE reaction were 
sequenced. The initial sequence information indicated that 2 almost identical cDNA 
species were cloned. On the basis of the initial sequencing results, new trypsinogen-
specific primers were designed. The GP2 sense primer (5'- AGC TAC AGC AGC AGC 
ACC CTG AAC -3') anneals to codons 98-105, and the GP2 antisense primer (5'- GAT 
CTG TCC AGG ATA GGC GGA CTG -3') anneals to codons 172-179 (Fig 2). Using the 
GP2 primers and the Universal primer additional trypsinogen-specific amplicons were 
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generated from the first-strand 5' RACE and 3' RACE cDNA and subcloned into the pCR-
Blunt II-TOPO vector. Five clones from the 5' RACE reaction and 4 clones from the 3' 
RACE reaction were sequenced. Finally, the full length cDNA sequences of the 2 guinea 
pig pre-trypsinogen isoforms were reconstructed from overlapping fragments. The guinea 
pig pre-trypsinogen cDNA sequences have been deposited to GenBank under accession 
numbers EF371801 and EF371802. 
2.2.4. Assay of trypsin activity. Trypsin activity was determined using the 
synthetic chromogenic substrate N-CBZ-Gly-Pro-Arg-p-nitroanilide. Kinetics of the 
chromophore release was followed at 405 nm in 0.1 M Tris-HCl (pH 8.0), 1 mM CaCl2, at 
22 oC using a Spectramax Plus 384 microplate reader (Molecular Devices Corp., 
Sunnyvale, CA, USA).  
Human trypsinogens were expressed in Escherichia coli and affinity-purified as 
described previously [47, 29, 48, 49]. Human pro-enteropeptidase (0.07 mg/mL stock 
solution) was activated with 50 nM human cationic trypsin in 0.1 M Tris-HCl (pH 8.0), 10 
mM CaCl2 and 2 mg/ml bovine serum albumin (final concentrations) for 30 min at room 
temperature. Before use, cathepsin B was activated with 1 mM dithiothreitol (final 
concentration) for 30 min on ice. 
 2.2.5. Study population. The study (screening of human chymotrypsin C gene) 
was approved by the medical ethical review committees of the University of Leipzig and 
the Charite´ University Hospital. All affected individuals gave informed consent. We 
enrolled 1,320 unrelated individuals with the diagnoses of hereditary (n = 143) or 
idiopathic chronic pancreatitis (n=758) or alcoholic chronic pancreatitis (n = 348) and 
originating from Germany. In addition, we also investigated subjects affected with tropical 
calcific pancreatitis originating from India (n = 71). The diagnosis of chronic pancreatitis 
was based on two or more of the following findings: presence of a typical history of 
recurrent pancreatitis, pancreatic calcifications and/or pancreatic ductal irregularities 
revealed by endoscopic retrograde pancreaticography or by magnetic resonance imaging of 
the pancreas, and pathological sonographic findings. Hereditary chronic pancreatitis was 
diagnosed when one first-degree relative or two or more second-degree relatives suffered 
from recurrent acute or chronic pancreatitis without apparent precipitating factors. 
Affected individuals were classified as having idiopathic chronic pancreatitis when 
precipitating factors, such as alcohol abuse, trauma, medication, infection, metabolic 
disorders or a positive family history consistent with hereditary pancreatitis, were absent. 
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Alcohol-induced chronic pancreatitis was diagnosed in patients who consumed more than 
60 g (females) or 80 g (males) of ethanol per day for more than 2 years. Control subjects 
free of pancreatic diseases were recruited from Germany (n = 2,804) and India (n = 81). 
The German controls included parents of children recruited to the German Multicenter 
Allergy Study, healthy controls recruited for a genetic study on type 2 diabetes at the 
University Hospital at Leipzig, blood donors, medical students, and staff and subjects 
recruited to the Berlin Aging Study. In addition, 432 German subjects with alcoholic liver 
disease but without pancreatic disease were recruited as controls for the alcoholic chronic 
pancreatitis group.   
2.2.6. Mutation screening. Genomic DNA was extracted from whole blood 
samples. Oligonucleotide sequences, PCR and cycle sequencing conditions are available in 
the Annex (see Supplementary methods). Briefly, we digested the PCR products with 
shrimp alkaline phosphatase and exonuclease I and performed cycle sequencing using 
BigDye terminator mix (Applied Biosystems). The reaction products were purified with 
ethanol precipitation or Sephadex G-50 and loaded onto an ABI 3100 or an ABI 3730 
sequencer (Applied Biosystems). 
2.2.7. Plasmid construction and mutagenesis. We constructed the           
pcDNA3.1(-)_CTRC (human chymotrypsinogen C) expression plasmid using the IMAGE 
clone #5221216 (GenBank: BI832476), as described by Szmola R et al. [16]. 
Chymotrypsinogen C mutants and the Glu-Glu-tagged constructs were generated by 
overlap extension PCR mutagenesis and ligated into pcDNA3.1(-). The Glu-Glu tag 
sequence (EYMPME) is derived from the polyoma virus medium T antigen. 
2.2.8. Transfection of human embryonic kidney 293T and AR42J cells. 
Human embryonic kidney (HEK) 293T cells were cultured and transfected as described 
[50]. Approximately 106 cells per well were plated in six-well tissue culture plates in 
Dulbecco's Modified Eagle's Medium (DMEM) (Invitrogen) supplemented with 10% fetal 
bovine serum (FBS) and 4 mM glutamine.We carried out transfections using 4 mg 
pcDNA3.1(–)-CTRC plasmid (carrying the wild type or the mutant CTRC variants) and 10 
ml Lipofectamine 2000 (Invitrogen) in 2 ml OptiMEM medium (Invitrogen) supplemented 
with 2 mM glutamine. After 5 h incubation at 37 °C , 2 ml DMEM with 20% FBS and 4 
mM glutamine was added to each well, and cells were incubated for an additional 24 h. 
Then we washed the cells with 1 ml OptiMEM and 2 mM glutamine and replaced the 
transfection medium with 2 ml OptiMEM and 2 mM glutamine. Time courses of 
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expression were measured starting from this medium change and were followed for 48 h. 
AR42J cells were maintained as subconfluent cultures in DMEM containing 20% FBS, 4 
mM glutamine and 1% penicillin/streptomycin solution. Cells (106/well) were plated into 
35-mm wells and grown in the presence of 100 nM dexamethasone for 48 h. We carried 
out transfections using the Glu-Glu–tagged CTRC constructs, as described above. After   
48 h, we replaced the medium with fresh OptiMEM and 2 mM glutamine, and we added 1 
nM cerulein (final concentration) to stimulate secretion. After 15 min of incubation, the 
medium was collected and analyzed by protein blotting. 
2.2.9. Chymotrypsin C activity assay. The conditioned medium was 
supplemented with 0.1 M Tris-HCl (pH 8.0) and 10 mM CaCl2 (final concentrations) and 
CTRC was activated with 100 nM human cationic trypsin (final concentration) for 20 min 
at 37 oC. We measured CTRC activity with Suc-Ala-Ala-Pro-Phe-p-nitroanilide or Glt-
Ala-Ala-Pro-Leu-p-nitroanilide (0.15 mM final concentration) in 0.1 M Tris-HCl (pH 8.0), 
1 mM CaCl2, at room temperature. 
2.2.10. Protein blotting. Samples were run on 15% Tris-glycine gels under 
reducing conditions and transferred onto an Immobilon-P membrane (Millipore) at 300 
mA for 1 h. The membrane was blocked with 5% non-fat dry milk overnight and incubated 
with a horse radish peroxidase-conjugated goat polyclonal antibody against the Glu-Glu 
tag at a concentration of 0.1 µg/mL for 1 h at room temperature. Horse radish peroxidase 
was detected using the SuperSignal West Pico Chemiluminescent Reagent (Pierce, 
Rockford, IL, USA). 
2.2.11. Isolation and culture of ducts. Small intra/interlobular ducts were 
isolated from the pancreas of guinea pigs weighing 150-250g. The guinea pig was humanly 
killed by cervical dislocation, the pancreas was removed and intra/interlobular ducts were 
isolated as described previously [51, 52, 53, 54]. The ducts were cultured overnight in a 37 
oC incubator gassed with 5 % CO2/95 % air. During the overnight incubation both ends of 
the isolated ducts seal and the ducts swell due to fluid secretion into the lumen [55].  
2.2.12. Microperfusion of pancreatic ducts. The lumen of the cultured ducts 
was microperfused using a modification of the method described by Ishiguro et al [56]. 
Briefly, one end of a sealed duct was cut off using a 26G x ½" (ø 0.45 x 12mm) medical 
stainless-steel needle, and the duct was transferred into a perfusion chamber mounted on 
the stage of an IX71 inverted Olympus microscope (Olympus, Budapest, Hungary). Two 
concentric pipettes were used for the microperfusion of the ducts. The sealed end of the 
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duct was aspirated into the outer, holding pipette, then the inner, perfusion pipette, was 
gently inserted into the lumen while a negative pressure was applied to the holding pipette 
using a syringe. The duct was then perfused at a rate of 10-30 µl/min, the luminal perfusate 
left the duct at the open end. The high rate of the bath perfusion (5-6 ml/min), which was 
in the same direction as the flow of luminal perfusate, ensured that the outgoing luminal 
perfusate did not gain access to the basolateral surface of the duct cells. Replacement of the 
luminal perfusate took up to 2 minutes.  
2.2.13. Measurement of intracellular calcium. Intracellular calcium 
concentration [Ca2+]i was estimated using the Ca2+-sensitive fluorescent dye FURA 2-AM. 
In the basolateral experiments sealed, cultured pancreatic ducts were attached to a glass 
coverslip (ø 24 mm), using the cell adhesive Cell-Tak, forming the base of a perfusion 
chamber mounted on an Olympus microscope. The ducts were then bathed in the standard 
Hepes solution at 37 oC and loaded with the membrane permeable acetoxymethyl 
derivative of FURA 2 (5 µmol/L) for 60 min. After loading, the ducts were continuously 
perfused with solutions at a rate of 5-6 mL/min. In the microperfusion experiments, ducts 
were loaded first with 5 µmol FURA 2-AM in standard Hepes solution for 60 min and than 
microperfused as described above. [Ca2+]i was measured using a CellR imaging system 
(Olympus, Budapest, Hungary) on 4-5 small areas (Region of interests – ROIs) of 5-10 
cells in each intact duct. For excitation, 340 and 380 nm filters were used, and the changes 
in [Ca2+]i were calculated from the fluorescence ratio (F340/F380) measured at 510 nm. One 
Ca2+i measurement was obtained per second.  
2.2.14. Immunohistochemistry. The pancreatic tissues were fixed in 10% neutral 
buffered formalin for 24 hours. Paraffin embedded, 3-4 µm thick sections were used for 
immunohistochemistry. The slides were treated for 30 minutes with target retrieval 
solution (DAKO, Glostrup, Denmark) in a microwave oven, followed by incubation with 
the primary antibodies (Santa Cruz Biotechnology, Inc., Heidelberg, Germany) in 1:100 
dilution at room temperature for 1 hour. PAR-2 antibody was a rabbit polyclonal antibody. 
Biotinylated secundary antibody (DAKO, LSAB kit) with diaminobenzidin (DAB) was 
used for visualization and counterstained with hematoxylin. Negative controls for 
nonspecific binding were incubated with secondary antibodies only, were processed and 
revealed no signal. Positive controls recommended by the manufacturer (Santa Cruz 
Biotechnology, Inc., Heidelberg, Germany) were used to confirm correct 
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immunohistochemical staining for PAR-2, that is normal brain. Reactions were scored 
positive where linear membrane staining was seen. 
2.2.15. Ethics. All experiments were conducted in compliance with the Guide for 
the Care and Use of Laboratory Animals (U.S.A. NIH publication No 85-23, revised 
1985). In addition, the experimental protocol was approved by the local Ethical Board of 
the University of Szeged, Hungary. 
2.2.16. Statistics. The significance of the differences between CTRC mutation 
frequencies in affected individuals and controls were tested by two-tailed Fisher's Exact 
Test. Additional odds ratios were calculated using SAS/STAT software (v 9.1) and 
GraphPad Prism (v 4.03). 
Results of the calcium measurements are expressed as means ± S.E.M (n = 5 to 7 ducts / 20 
to 35 ROIs). Statistical analyses were performed using ANOVA. P values ≤ 0.05 were 
accepted as significant. 
2.2.17. Accession codes. Entrez nucleotide: chymotrypsin C (CTRC): 
NT_004873 (chromosome 1 genomic contig); NM_007272 (human CTRC mRNA 
sequence); BI832476 (IMAGE clone used for plasmid construction). Protein Data Bank: 
chymotrypsinogen C crystal structure, 1PYT.  
3. RESULTS 
3.1. Purification of guinea pig trypsinogens.  
Homogenate of guinea pig pancreas was applied to an ecotin-affinity column and 
the SDS-PAGE analysis of the given eluate revealed two closely migrating bands, a lighter 
upper band and a strong lower band, indicating that at least 2 different proteins were 
present in the ecotin eluate (Fig 1). To resolve these proteins, the ecotin eluate was loaded 
onto a Mono S cation-exchange column equilibrated with 20 mM Na-acetate (pH 5.0) and 
eluted with a NaCl gradient (0-0.5 M). A single major peak was eluted at approximately 
0.15 M NaCl concentration (Fig 1A), which was identified as trypsinogen on the basis of 
its enzymatic activity after activation with enteropeptidase. In addition, a small, broader 
peak was eluted at approximately 0.22 M NaCl, which exhibited both trypsin and 
chymotrypsin activity upon activation with enteropeptidase or trypsin, respectively. 
Although not shown, the number of peaks eluted did not change when the NaCl gradient 
was extended to 1.0 M. Aliquots of fractions were analyzed by SDS-PAGE and Coomassie 
Brilliant Blue R-250 staining. The first, main peak showed only a single band, whereas the 
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second peak contained two bands, one of which co-migrated with the trypsinogen band 
recovered in the first peak (Fig 1B). Samples were shipped to Midwest Analytical Inc. for 
N-terminal sequencing. N-terminal sequencing of the first, major trypsinogen peak 
revealed a single, homogeneous sequence of Leu-Pro-Ile-Asp-Asp, suggesting that this 
peak contains a single trypsinogen isoform. This trypsinogen isoform was novel, as the N-
terminal sequence determined was distinct from the known trypsinogen sequences found in 
protein databases. The second peak contained a mixture of two different N-terminal 
sequences, a trypsinogen N terminus identical to the one found in the first, major peak and 
a chymotrypsinogen-like N terminal sequence of Cys-Gly-Val-Pro-Ala. Therefore, the 
enzyme activity assays and N terminal sequencing are in agreement demonstrating that the 
smaller Mono S peak contains a mixture of a trypsinogen and a chymotrypsinogen. The 
identical N-terminal sequences of the trypsinogens recovered in the first and second peaks 
suggested that the two peaks contained the same isoform and the small second trypsinogen 
peak represented an oligomeric or aggregate form of guinea pig trypsinogen. This 
conclusion was also supported by comparative MS/MS peptide sequencing of trypsinogens 
from the two peaks. 
 
 
Figure 1. Purification of the guinea pig trypsinogen. (A) Mono S ion-exchange chromatogram of the guinea pig 
trypsinogens eluted from the ecotin affinity column.  See text for details.  The Mono S column was developed with a 
0-0.5 M gradient of NaCl at a flow rate of 1 mL/min. (B)  SDS-PAGE analysis of the ecotin-eluate (E, 50 µL loaded; 
~15 µg protein) and Mono S peaks 1 and 2 (100 µL from the 1 mL fraction loaded; ~15 µg protein).  Samples were 
precipitated with trichloroacetic acid (10 % final concentration); solubilized in reducing Laemmli sample buffer, heat-
denatured, electrophoresed on 13 % minigels, and stained with Coomassie Brilliant Blue R-250.  MultiMark multi-
colored standards (Invitrogen) were used as molecular weight markers (M). 
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3.2. MS/MS peptide sequencing of purified guinea pig trypsinogen.  
The previously mentioned two bands of the second peak of Mono S chromatogram 
(Fig 1.) were subjected to tandem MS (mass spectrometric) peptide sequencing by 
ProtTech, Inc, Eagleville, PA, USA (see also Methods 2.2.2). The following tryptic 
peptides were sequenced. LPIDDDDK (from Leu16 to Lys23); VSEGSEQFITASK (from 
Val80 to Lys92); HPSYSSSTLNNDIMLIK (from His96 to Lys112); and LASAANLNSK 
(from Leu113 to Lys122). Although this approach yielded about 20 % coverage of the 
protein sequence; the peptides sequenced were in perfect agreement with the amino-acid 
sequence predicted from the cloned cDNA. The trypsinogen band from the small, second 
Mono S peak was also subjected to MS/MS analysis and the exact same tryptic fragments 
were identified, confirming that this peak contained the same isoform of trypsinogen as the 
first main Mono S peak.  
 
3.3. Complementary DNA cloning of guinea pig trypsinogens. 
  To determine the complete cDNA sequence of the guinea pig trypsinogen(s), we 
utilized a PCR-based cloning method after 5' and 3' RACE, as described in the Methods. 
The assembled cDNA sequences were essentially identical with the exception of 2 
positions (Fig 2). Thus, at c.43 (in codon 15) a G/T variation was observed, whereas at 
c.276 (in codon 92) an A/G variation was found. The variant with c.43G and c.276A was 
arbitrarily designated as isoform 1 and the variant with c.43T and c.276G as isoform 2. The 
sequences of the 2 isoforms have been deposited with GenBank under accession numbers 
EF371801 and EF371802. The relative amounts of the two isoforms at the mRNA level 
appeared to be comparable, as judged from the isoform distribution of the sequenced 5' 
RACE clones. The G/T variation at codon 15 affects the encoded amino acid, which is 
predicted either as Ala (GCC) or Ser (TCC). In contrast, the G/A variation at position 92 
has no affect at the protein level as both AAG and AAA codons encode for Lys. The 
deduced amino-acid sequences of the 2 isoforms differ only in amino-acid 15, which is 
either Ala or Ser. Position 15 is the last amino-acid of the secretory signal peptide, which is 
removed upon entry into the endoplasmic reticulum. The mature trypsinogens resulting 
from the two variants are thus identical, and the guinea pig pancreas secretes a single 
trypsinogen isoform. 
 The guinea pig pre-trypsinogens are composed of 246 amino acid residues, and the 
231 amino-acid long mature trypsinogen has a predicted molecular weight of 24,378.5 Da.  
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The guinea pig trypsinogen is cationic in character, with a theoretical pI value of 8.0 
(http://ca.expasy.org/tools/protparam.html). The N-terminal 15 amino acids form the signal 
peptide, which is followed by the 8 amino-acid long trypsinogen activation peptide 
including the highly conserved tetra-aspartate motif (Fig 2). Importantly, the predicted and 
experimentally determined N-terminal sequences of guinea pig trypsinogen are in perfect 
agreement. The molecule is stabilized by 6 disulfide bridges, characteristic of most 
vertebrate trypsinogens. Acidic determinants of the calcium-binding loop are also fully 
conserved (Glu75, Glu82 and Glu85). Similarly to human mesotrypsinogen, position 79 is 
Lys in the guinea pig trypsinogen, instead of the more typical Glu found in other 
mammalian trypsinogens. The functional role of this side-chain is unclear, but the 
Glu79→Lys mutation (E79K) in human cationic trypsinogen seems to be associated with 
chronic pancreatitis [57]. It is interesting to note that the otherwise highly conserved 
Arg122 is replaced with a Lys in the guinea pig trypsinogen. Arg122 is a trypsin sensitive 
site, which is believed to be important for autocatalytic degradation of bovine, rat and 
human trypsins [58, 59]. Mutation of Arg122 to His causes hereditary chronic pancreatitis 
in humans [28]. Relative to human trypsinogens, there is a low ratio of charged side-chains 
in the guinea pig trypsinogen (Arg, Lys, Asp and Glu residues; 11.3 % in guinea pig 
trypsinogen versus 18.1 % in both human trypsinogens), and a higher abundance of Ser 
residues (14.3 % in guinea pig trypsinogen versus 8.6 % and 10.3 % in human cationic and 
anionic trypsinogens, respectively). The guinea pig trypsinogen exhibits the strongest 
similarity to the bovine cationic trypsinogen (82 % identity), whereas the identity with 
human cationic and anionic trypsinogens are 76 % and 75 %, respectively. 
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Figure 2. Complementary DNA and deduced amino acid sequence of guinea pig pre-trypsinogens. Amino-acid   
numbering starts with the initiator methionine codon.  Isoform 1 is shown, with the nucleotide differences present in 
isoform 2 indicated by purple superscripts. Note that Ala15 becomes Ser16 in isoform 2, whereas Lys92 remains 
unchanged.  The sequences where the GP1 and GP2 primers anneal are underlined (grey). The highly conserved 
catalytic Ser200, typical of serine proteases, is highlighted in yellow. The activation peptide is shown in green. 
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Figure 4. Activation of trypsinogen by cathepsin B. Guinea pig 
trypsinogen (open circles) and human cationic trypsinogen (solid 
squares) were activated at 2 µM concentration with human cathepsin 
B (90 µg/mL) at 37 °C in 0.1 M sodium acetate buffer (pH 4.0) in the 
presence of 1 mM dithiothreitol, 2 mg/mL bovine serum albumin, 1 
mM K-EDTA and 0.3 mM benzamidine. Aliquots (2 µL) were 
withdrawn at indicated times and trypsin activity was measured on the 
synthetic substrate. 
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Figure 3. Activation of trypsinogen by enteropeptidase. (A) Approximately 2 µM (final concentration) of guinea pig 
trypsinogen (open circles) and human cationic trypsinogen (solid squares) were incubated with 28 ng/mL enteropeptidase 
(final concentration) at 37 °C, in 0.1 M Tris-HCl (pH 8.0), 2 mg/mL bovine serum albumin and 1 mM CaCl2 in a final 
volume of 100 µL.  Aliquots of 2 µl were withdrawn from reaction mixtures at the indicated times, and trypsin activity was 
determined with the synthetic substrate N-CBZ-Gly-Pro-Arg-p-nitroanilide. Trypsin activity was expressed as a percentage 
of full activity. (B) Samples (100 µL) were precipitated with 10 % trichloroacetic acid (final concentration) at the indicated 
times and analyzed by reducing SDS/PAGE (13%) and Coomassie Brilliant Blue R-250 staining. 
3.4. Activation of guinea pig trypsinogen.  
 Activation characteristics and catalytic properties of guinea pig trypsinogen were 
compared to those of human anionic and cationic trypsinogens, which comprise 90-95 % 
of trypsinogens in humans. The physiological activator enteropeptidase readily activated 
guinea pig trypsinogen at pH 8.0, although at a rate that was slower than activation of 
human cationic trypsinogen (Fig 3). Similarly, activation of guinea pig trypsinogen by the 
pathological activator cathepsin B at pH 4.0 was slower, but still significant, relative to 
human cationic trypsinogen (Fig 4). Because we used human enteropeptidase and 
cathepsin B preparations in our 
experiments, the observed 
differences in activation rates 
between the human and guinea pig 
trypsinogens should be interpreted 
cautiously. The important 
conclusion of the experiments in 
Figs. 3 and 4 is that both 
enteropeptidase and cathepsin B 
can activate guinea pig trypsinogen 
under certain conditions. 
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Figure 5. Trypsin-mediated trypsinogen activation (autoactivation). Guinea pig trypsinogen (open circles), human 
cationic trypsinogen (solid squares) and human anionic trypsinogen (solid triangels) were activated with their respective 
trypsins. The reactions were carried out at 37 °C, using 2 µM trypsinogen, 1 mM CaCl2, 0.1 M Tris-HCl (pH 8.0), and 
200 nM trypsin initial concentrations. Although not shown, increasing the CaCl2 concentration to 10 mM had no 
measurable stimulatory effect on the autoactivation of guinea pig trypsinogen in this time range. 
 
 In contrast, a completely different picture emerged when autoactivation of guinea 
pig trypsinogens and human trypsinogens were compared. Human anionic and cationic 
trypsinogens autoactivated rapidly, whereas guinea pig trypsinogen exhibited essentially 
no autoactivation (Fig 5).  
3.5. Catalytic activity and autolysis of guinea pig trypsin.  
 Catalytic parameters of guinea pig trypsin were determined on the peptide substrate 
N-CBZ-Gly-Pro-Arg-p-nitroanilide. The kcat and KM values were similar to those of human 
trypsins, indicating that lack of autoactivation (see above) was not due to a catalytic defect 
in guinea pig trypsin (Table 2.). 
 
  
kcat (s-1) KM (µM) kcat/KM (M-1·s-1) 
guinea pig 115.6 14.6 7.9 x 106 
human cationic 85.3 17.6 4.8 x 106 
 
Table 2.  Kinetic parameters of guinea pig trypsin and human cationic trypsin on the synthetic substrate N-CBZ-
Gly-Pro-Arg-p-nitroanilide. 
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Figure 6. Autocatalytic degradation (autolysis) of trypsin. Guinea pig trypsinogen (open circles), human cationic 
trypsinogen (solid squares), and human anionic trypsinogen (solid triangles) were activated at 2 µM concentration with 
enteropeptidase for 60 min at 37 °C in the presence of 1 mM CaCl2. Autocatalytic inactivation of trypsins was then 
followed at 37 °C after addition of K-EDTA (pH 8.0) to a final concentration of 2 mM. Residual activities were 
expressed as percentage of the full trypsin activity measured after enteropeptidase activation.  
 Autocatalytic degradation (autolysis) of guinea pig trypsin was also measured. 
Figure 6 demonstrates that at pH 8.0, in the absence of Ca2+, the guinea pig trypsin 
underwent relatively slow autolysis at an intermediate rate between those of the two human 
trypsins. As observed previously, human cationic trypsin was resistant to autolysis, 
whereas anionic trypsin rapidly autodegraded [60, 61]. 
3.6. DNA sequencing of the human chymotrypsin C gene. 
 We carried out direct DNA sequencing of all eight exons of the 8.2-kb 
chymotrypsin (CTRC) gene in 621 individuals with idiopathic or hereditary chronic 
pancreatitis and in 614 control subjects of German origin (see Method 2.2.5.). We found 
several CTRC variants, the large majority of which affected exons 2, 3 and 7. Therefore, 
we extended our analyses by sequencing an additional 280 affected individuals for these 
three exons and an additional 2,075 controls for exons 2 and 3 and 2,190 controls for exon 
7. Altogether, we identified 11 missense and 2 deletion variants in CTRC (Table 3). The 
two most frequent variants, c.760C4T (p.R254W) and c.738_761del24 (p.K247_R254del), 
both located in exon 7, were found in affected individuals with a frequency of 2.1% and 
1.2%, respectively. Taken together, the two alterations were significantly overrepresented 
in the pancreatitis group (30 of 901; 3.3%) compared to controls (21 of 2,804; 0.7%) (OR 
= 4.6; CI = 2.6–8.0; P = 1.3 x 10-7). Variant c.738_761del24, which causes an in-frame 
deletion of eight amino acids from Lys247 through Arg254 (p.K247_R254del), showed the 
strongest disease association (OR = 11.5; CI = 3.2–41.5; P = 0.00003). Subgroup analysis 
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for these two heterozygous variants showed similar frequency in the hereditary (6 of 143; 
4.2%; 6 _ p.R254W) and idiopathic (24 of 758; 3.2%; 13 _ p.R254W; 11 _ 
p.K247_R254del) groups (Table 3). One individual with idiopathic disease was compound 
heterozygous for p.V235I (inherited from the mother) and p.R254W (inherited from the 
father). 
P values were determined by Fisher's Exact Test. * all affected individuals against controls 
ICP, idiopathic chronic pancreatitis; HP, hereditary chronic pancreatitis 
 
Table 3. CTRC variants detected in German subjects with idiopathic or hereditary chronic pancreatitis and 
healthy controls.  
 
 To confirm our findings in an independent cohort affected with another 
inflammatory pancreatic disease, we sequenced all eight exons of CTRC in 96 German 
individuals affected with alcohol-related chronic pancreatitis. Subsequently, we sequenced 
exons 2, 3 and 7 in an additional 252 subjects (348 subjects in total) with alcoholic chronic 
pancreatitis. For controls, we analyzed exons 2, 3 and 7 in 432 German individuals with 
alcoholic liver disease but without chronic pancreatitis. Again, we found a significant 
enrichment of the two exon 7 variants, p.R254W and p.K247_R254del, in subjects with 
alcoholic pancreatitis (10 of 348; 2.9%) versus subjects with alcohol-related liver disease 
(3 of 432; 0.7%) (OR = 4.2; CI = 1.2–5.5; P = 0.02; Table 4). 
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Exon 
Nucleotide 
change 
Amino acid 
change 
Affected 
individuals 
 
Controls 
 
P 
value 
 
OR 
 
95% 
CI 
        2 c.110G>A p.R37Q 0/348 (0%) 3/432 (0.7%) 0.26 - - 
7 c.649G>C p.G217R 1/348 (0.3%) 0/432 (0%) 0.45 - - 
7 c.703G>A p.V235I 1/348 (0.3%) 1/432 (0.2%) 1.0 - - 
7 c.746C>T p.P249L 1/348 (0.3%) 0/432 (0%) 0.45 - - 
7 c.760C>T p.R254W 8/348 (2.3%) 2/432 (0.5%) 0.03 5.1 1.1-
24.0 
7 c.738_761del24 p.K247_R254del 2/348 (0.6%) 1/432 (0.2%) 0.58   
 
P values were determined by Fisher's Exact Test. 
Table 4. CTRC variants detected in German subjects with alcohol-related chronic pancreatitis and controls with 
alcoholic liver disease without pancreatitis. 
 
Finally, to investigate the significance of CTRC variants in chronic pancreatitis in subjects 
of non-European descent, we analyzed 71 individuals affected with tropical pancreatitis 
and 84 controls of Indian origin. Notably, the frequency of CTRC alterations in subjects 
with pancreatitis was even higher in this cohort (Table 5). 
 
Exon 
Nucleotide 
change 
Amino acid 
change 
Affected 
individuals 
 
Controls 
 
P value 
 
OR 
 
95
% 
CI 
        
3 c.190_193delATTG p.I64LfsX69 2/71 (2.8%) 0/84 (0%) 0.21 - - 
3 c.217G>A p.A73T 4/71 (5.6%) 0/84 (0%) 0.04 11.3 0.6-
213 
7 c.703G>A p.V235I 1/71 (1.4%) 0/84 (0%) 0.46 - - 
7 c.760C>T p.R254W 2/71 (2.8%) 1/84 (1.2%) 0.60 - - 
7 c.778G>A p.D260N 1/71 (1.4%) 0/84 (0%) 0.46 - - 
     
   All  
 10/71 (14.1%) 1/84 (1.2%) 0.0028 13.6 1.7-
109.
2 
 
P values were determined by Fisher's Exact Test. 
Table 5. CTRC variants detected in subjects with tropical pancreatitis and healthy controls of Indian origin. 
 
 
Overall, 14.1% of affected individuals but only 1.2% of controls carried a CTRC variant 
(OR = 13.6; CI = 1.7–109.2; P = 0.0028). Two relatively frequent variants found in Indians 
were absent in Germans: the c.217G4A (p.A73T) missense alteration and the 
c.190_193delATTG (p.I64LfsX69) frameshift deletion. On the other hand, the 
p.K247_R254del variant that was relatively frequent in affected individuals from Germany 
was not found in the Indian population, and the enrichment of the p.R254W variant in 
subjects with tropical pancreatitis did not reach statistical significance. However, because 
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of the significantly smaller size of the Indian cohort relative to the German cohort, caution 
is warranted in the interpretation of these differences. Nonetheless, the data clearly indicate 
that CTRC variants increase the risk for tropical pancreatitis as well. 
3.7. Examination of the effects of pancreatitis associated CTRC variants on 
the secretion of chymotrypsinogen C.  
 To investigate the functional consequences of the CTRC missense alterations and 
the p.K247_R254del in-frame deletion, we expressed wild-type and mutant CTRC in HEK 
293T cells via transient transfection. Strikingly, secretion of p.K247_R254del and p.A73T 
was severely diminished relative to the wild-type, as evidenced by the loss of CTRC 
activity in enzyme assays and the faint protein bands on gels (Fig 7A and 7B). When these 
two mutants were partially purified to test their activity, p.K247_R254del proved 
catalytically inactive, whereas p.A73T exhibited measurable protease activity (data not 
shown). In contrast to the almost complete loss of function observed with p.K247_R254del 
and p.A73T, CTRC activity secreted by cells expressing the p.R254W mutant was reduced 
to about 40% of wild-type (Fig 7A). SDS-PAGE of conditioned media revealed that 
secreted levels of p.R254W were about 50% less than wild-type CTRC, suggesting that the 
functional defect in this mutant is decreased secretion rather than impaired catalytic 
activity (Fig 7B). This conclusion was strengthened by enzyme kinetic analysis of purified 
wild-type and p.R254W mutant CTRC. Kinetic parameters compared on two different 
chromogenic peptide substrates were essentially identical (Table 6), indicating that reduced 
function of p.R254W is solely due to decreased secretion.  
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Figure 7. Effects of pancreatitis associated CTRC variants on the secretion of chymotrypsinogen C. (A) HEK 293T 
cells were transfected with the indicated constructs, and aliquots of conditioned media were withdrawn at the given times. 
CTRC activity was determined after activation with trypsin, as described in the Methods, and expressed as percentage of 
the maximal activity, which corresponded to 14.7 µM p-nitroaniline released per minute. (B) Aliquots (0.15 mL) of 
conditioned media of transfected HEK 293T cell were precipitated with 10% trichloroacetic acid (final concentration) and 
analyzed by SDS-PAGE and Coomassie Brilliant Blue R-250 staining (left panel). Alternatively, AR42J cells were 
transfected with Glu-Glu tagged versions of wild-type and mutant CTRC constructs and conditioned media were analyzed 
by Western blotting using an antibody against the Glu-Glu tag. 
 Suc-Ala-Ala-Pro-Phe-p-nitroanilide 
 
 wild type R254W 
KM 10.3 ± 0.4 µM 11.0 ± 1.1 µM 
kcat 4.7 ± 0.1 s-1 4.1 ± 0.1 s-1 
kcat/KM 4.6*105 M-1 s-1 3.7*105 M-1 s-1 
 
           Glt-Ala-Ala-Pro-Leu-p-nitroanilide 
 
 
wild type R254W 
KM 2.3 ± 0.2 µM 3.9 ± 0.5 µM 
kcat 2.3 ± 0.1 s-1 2.2 ± 0.1 s-1 
kcat/KM 1.0*106 M-1 s-1 5.6*105 M-1 s-1 
 
Table 6. Kinetic parameters of wild-type CTRC and mutant p.R254W on chromogenic peptide substrates in 0.1 M 
Tris-HCl (pH 8.0), 1 mM CaCl2, at room temperature. 
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To demonstrate that the clinically significant CTRC mutants are also poorly secreted in 
cells that more closely resemble human pancreatic acinar cells, we performed additional 
transfection experiments with the AR42J rat acinar cell line [62]. Wild-type CTRC and 
mutants p.A73T, p.K247_R254del and p.R254W were tagged with a Glu-Glu affinity tag 
to allow specific detection in the background of the native chymotrypsinogens secreted by 
AR42J cells. Stimulation of transfected cells with the cholecystokinine analog cerulein 
resulted in secretion of immunoreactive wild-type and somewhat less p.R254W mutant, 
whereas p.A73T and p.K247_R254del were not secreted to detectable levels (Fig 7B). 
 In addition to the frequent CTRC alterations mentioned above, we also analyzed the 
variants p.R37Q, p.Q48R, p.G217S, and p.V235I by transient transfections in HEK 293T 
cells (Fig 8). Variant p.R37Q exhibited essentially normal activity and secretion (~82-88 % 
of wild-type). In contrast, no CTRC activity was measurable from conditioned media of 
cells transfected with mutant p.Q48R and SDS-PAGE revealed a significant secretion 
defect (~30 % of wild type). We also found that mutant p.Q48R underwent degradation 
during trypsin-mediated activation, presumably because the mutation introduced a new 
trypsin sensitive site (not shown). Mutant p.G217S showed significant catalytic 
impairment (specific activity only ~7 % of wild type) and a modest decrease in secretion 
(~70 % of wild type). Finally, CTRC activity secreted by cells transfected with variant 
p.V235I was moderately reduced (~65 % of wild type); which seemed to be due to a 
combination of slightly lower specific activity and slightly reduced secretion of CTRC 
protein. Figure 9 summarizes the secretion of all the examined chymotrypsinogen C 
variants in percentage relative to wild type (Fig 9).  
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3.8. Molecular modeling of the CTRC mutations.  
 Molecular modeling indicates that p.K247_R254del eliminates the last of the 6 β-
strands of the C-terminal antiparallel β-barrel domain (Fig 10). A change of this magnitude 
in a structurally conserved part is expected to cause a folding defect, which might lead to 
the observed loss of catalytic function and the diminished secretion. Interestingly, 
p.R254W is also found within this deleted peptide segment. Variant p.A73T is located next 
to the catalytic His74 (His57 in the conventional chymotrypsin numbering), and thus might 
interfere with enzyme function. However, we found that the loss of function in p.A73T 
was caused by a marked secretion defect rather than catalytic impairment. Inspection of the 
atomic model reveals that Ala73 is in the vicinity of two hydrophobic side-chains, Trp113 
 
Figure 9. Summary of secretion of chymotrypsinogen C variants relative to wild type. The amount of secreted 
CTRC protein was determined by densitometry of dried gels stained with Coomassie Brilliant Blue R-250. Gels were 
scanned at 300 dpi resolution and CTRC bands were quantitated using the Volume Analysis tool of the Bio-Rad 
Quantity One software (ver. 4.4.0). The average of at least 3 experiments is shown; the standard deviation was within 
15 %.  
 
Figure 8. Effect of different CTRC variants on chymotrypsinogen C secretion. HEK 293T cells were 
transfected with the indicated constructs, and CTRC activity in the conditioned media was determined as described 
in the legend to Fig. 7 . 
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and Val109, suggesting that replacement of Ala73 by the more bulky and polar threonine 
results in unfavorable interactions with the surrounding hydrophobic residues and thereby 
in altered folding with consequent intracellular retention and degradation. 
 
3.9. Effect of trypsin and bile acids on the calcium signalling of pancreatic 
duct epithelial cells. 
 
It has been previously shown that activation of PAR-2 regulates the calcium 
signalling of pancreatic duct cells [43], so we performed experiments to reveal whether 
trypsin stimulates guinea pig pancreatic duct epithelial cells. Basolateral administration of 
trypsin dose-dependently triggered intracellular calcium release in the pancreatic duct 
cells, which showed a sharp initial peak followed by a rapid decrease (Fig 11A-E).  
 
 
 
 
 
 
 
 
 
 
Figure 10. Ribbon diagram of chymotrypsinogen C. The bovine chymotrypsinogen C molecule is shown, which 
was crystallized as part of a ternary complex with proproteinase E and procarboxypeptidase A (Protein Data Bank file 
1PYT). The position of Ala73 (mutated in p.A73T) is shown in red and Arg254 (mutated in p.R254W) is indicated in 
green. The yellow peptide segment is deleted in mutant p.K247_R254del. The image was rendered using 
DeepView/Swiss-PdbViewer v. 3.7 (www.expasy.org/spdbv/). 
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Figure 11. Trypsin increases intracellular calcium concentration in guinea pig pancreatic duct cells. (A-D) 
Representative traces show the effects of trypsin, which triggers dose-dependent calcium signals (10 nM-10 µM).      
(E) The bar chart shows the summary of results. Means ± SEM are from 4-6 individual ducts. * : p<0.001 vs. 0.01 µM. 
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The effect of trypsin on increase in [Ca2+]i  was totally blocked by soybean trypsin 
inhibitor (1mg/ml) (Fig 12A) and the Ca2+-chelator BAPTA-AM (20 µM) (Fig 12B). The 
removal of calcium from the extracellular solution did not reduce the rise in [Ca2+]i evoked 
by trypsin (Fig 12C). PAR-2 activating peptide (0.3 mM) could mimic the effect of the 
stimulatory effect of basolateral administration of trypsin (Fig 12D). Luminal 
administration of trypsin performed by the microperfusion technique (see Methods 2.2.12.) 
also caused calcium response in the cells, although, the registered calcium signal was 
lower and had a well-sustained plateau after the initial peak compared to the signals 
triggered by basolateral trypsin (Fig 12E). 
 
 
 
 
Figure 12. The effects of trypsin on [Ca2+]i. under different conditions. (A) Effect of basolateral trypsin after 
pretreatment of the 10 µM trypsin solution with 1 mg/ml (0.05 µM) soybean trypsin inhibitor (SBTI) for 30 min at room 
temperature. (B) Pretreatment of the duct cells with the calcium chelator BAPTA-AM (20 µM) for 30 min blocked the 
calcium response. (C) Deprivation of Ca2+ from the external solution did not modify the effects of trypsin on [Ca2+]i . 
(D) PAR-2 activating peptide mimicked the effect of trypsin. (E) Luminal administration of trypsin. The traces are 
representative of experiments performed on 4-7 individual ducts. 
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PAR-2 expression has been detected in dog [43], bovine [44] and human pancreatic 
duct cells [45]. We performed immunostaining of the guinea pig pancreas to identify PAR-
2 expressing cells. Surprisingly, pancreatic duct cells showed differential expression of 
PAR-2, as the receptor was expressed on the luminal membrane of intralobular ducts (Fig 
13A) but not in interlobular ducts, where PAR-2 was found in periductal nerves (Fig 13B). 
The receptor has also been detected in endothelial cells (Fig 13C) and in Langerhans islets 
(Fig 13D).      
We also examined whether bile acids can activate the calcium signalling 
mechanisms of pancreatic duct epithelial cells. Bile acids have been shown to evoke Ca2+ 
signalling in pancreatic acinar cells [35], therefore, we thought to test whether bile acids 
have any effect on [Ca2+]i in guinea pig pancreatic ducts.  
Figure 14A and B show that basolateral administration of chenodeoxycholate and 
glycochenodeoxycholate caused a dose-dependent increase in [Ca2+]i (Figs 14A and B).  
The unconjugated chenodeoxycholate was the most effective, causing what appeared to be 
repetitive [Ca2+]i transients at a dose of 0.1 mM and a large initial peak in [Ca2+]i  followed 
by a sustained plateau at 1 mM (Fig 14A). In contrast, 0.1 mM of the conjugated 
glycochenodeoxycholate had little or no effect on [Ca2+]i while 1 mM 
 
Figure 13. Localization of PAR-2 by immunohistochemical staining of the sections of the intact guinea pig 
pancreas using anti-PAR-2 antibody. (A) Expression of PAR-2 on the luminal membrane of intralobular ducts of the 
guinea pig pancreas (600x). The arrows indicate intensely stained cells. (B) Expression of PAR-2 in periductal nerves 
around interlobular ducts (600x). Asterisks denote the lumen of the pancreatic duct. Localization of PAR-2 in (C) 
endothelial cells (600x) and (D) Langerhans islets (600x). The asterisk on figure 13C denote the lumen of a pancreatic 
blood vessel.  
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glycochenodeoxycholate caused a small initial peak followed by a sustained plateau which 
was similar in magnitude to the plateau obtained with 1 mM chenodeoxycholate (Fig 14B).  
 
Luminal application of 0.1 mM chenodeoxycholate caused slow [Ca2+]i transients 
which appeared to decline during continued exposure to the bile acid. However, 1.0 mM 
luminal chenodeoxycholate caused a very large sustained increase in [Ca2+]i (Fig 14B). In 
contrast, 0.1 mM of the conjugated glycochenodeoxycholate had no effect on [Ca2+]i when 
applied from the lumen whereas 1 mM caused a rise in [Ca2+]i comparable to that observed 
when the same dose was applied from the basolateral membrane (compare figs. 14C and 
14D).  
Figure 15 shows fluorescent ratio images of perfused pancreatic ducts exposed to 
chenodeoxycholate, which confirm the results described above. Basolateral application of 
0.1 mM chenodeoxycholate caused localized increases in [Ca2+]i within the duct, whereas 
all cells appeared to be affected by 1 mM chenodeoxycholate. Following luminal 
application, localized increases in [Ca2+]i  were also observed with 0.1 mM 
 
 
Figure 14. Bile acids stimulate calcium signalling in guinea pig pancreatic ducts. The effect of basolateral 
(A,C) and luminal (B,D) 0.1-1 mM chenodeoxycholate (A,B) or glycochenodeoxycholate (C,D) on intracellular 
calcium concentration [Ca2+]i in standard Hepes solution. Chenodeoxycholate and glycochenodeoxycholate dose-
dependently increased the [Ca2+]i in each experiment. (B) 1 mM chenodeoxycholate caused the highest elevation in 
[Ca2+]i from the luminal membrane, while the low dose of glycochenodeoxycholate had only a slight effect on 
[Ca2+]i from the luminal membrane (D).  
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chenodeoxycholate, but these were more extensive compared to when the same dose was 
administered basolaterally. Luminal 1 mM chenodeoxycholate caused a very large 
generalized increase in [Ca2+]i.   
 
Neither atropine (100 µM) nor removal of extracellular Ca2+ had any effect on the 
[Ca2+]i rise evoked by basolateral administration of chenodeoxycholate (Fig 16A). 
However, the IP3 receptor antagonist caffeine (20 mM), the Ca2+-chelator BAPTA-AM (40 
µM), the IP3 receptor inhibitor xestospongin C (50 µM) and the phospholipase C inhibitor 
U73122 (10 µM) all completely blocked the rise in [Ca2+]i evoked by 0.1 mM 
chenodeoxycholate (Fig 16A). The inhibitors also reduced, albeit less so, the rise in [Ca2+]i 
evoked by 1 mM basolateral chenodeoxycholate (Fig 16B). Similar results were obtained 
when chenodeoxycholate was applied from the luminal membrane. 
 
Figure 15. Light and fluorescent ratio images of pancreatic ducts perfused with either 1 (panel A and B) or   
0.1 mM (panel C and D) chenodeoxycholate from either the luminal (panel A and C) or basolateral side (panel 
B and D). An increase in [Ca2+]i is denoted by a change from a ‘‘cold’’ color (blue) to a ‘‘warmer’’ color (yellow to 
red); see scale on the right. Fluorescent pictures (in middle and on the right side) were taken before and 1 min after 
exposure of the ducts to chenodeoxycholate.  
A 
 
 
 
 
B 
 
 
 
 
C 
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4. DISCUSSION 
 
Pancreatitis is the inflammation of the pancreas, which has two main forms: acute 
and chronic. Acute pancreatitis occurs suddenly and may result in life-threatening 
complications. The two most frequent etiological factors causing the acute form are 
blockage of the pancreatic duct by a gallstone or heavy alcohol ingestion. Other causes 
include hyperlipidemia, hypercalcemia, viral infection, and in a few cases, the disease can 
have autoimmune or hereditary origin [63]. Chronic pancreatitis is primarily caused by 
prolonged alcohol ingestion resulting in irreversible damage to the exocrine and endocrine 
pancreatic tissue. In a small percentage of the cases, especially at patients with young age, 
who do not consume alcohol, chronic pancreatitis tends to run in their families, suggesting 
a hereditary background [64].  
 
 
Figure 16. The effect of chenodeoxycholate on [Ca2+]i. under different conditions. Panel A shows the effect of 
luminal administration of chenodeoxycholate (0.1 and 1 mM). For positive control, 0.1 mM chenodeoxycholate was 
administered into the lumen. Withdrawal of extracellular calcium and the application of 100 µM atropine had no 
effect on chenodeoxycholate -induced Ca2+ release. However, preloading the ducts with BAPTA-AM (40 µM) and 
caffeine (20 mM) abolished the effect of chenodeoxycholate on [Ca2+]i. Panel B shows the effect of basolateral 
administration of chenodeoxycholate (0.1 and 1 mM). Controls represent response to chenodeoxycholate only. Means 
and SEM from 25 ROIs of 5 ducts are shown. a: p<0.001 vs. control, b: p<0.05 vs. the control. 
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 Development of in vivo experimental models of acute pancreatitis has enabled us to 
study the pathogenesis of the disease [65, 66, 67]. For example, administration of a 
supramaximally stimulating dose of cholecystokinin analog cerulein to rodents results in 
either mild (rats) or severe (mice) acute edematous pancreatitis which develops over hours 
[68, 69]. Other types include L-arginine- or L-ornithine-induced necrotizing [70, 71, 72, 
73, 74], bile acid-induced necrotizing and haemorrhagic [75, 76] types. These models are 
well-characterized in the rat and mouse but, surprisingly, only a few studies were 
published about experiments on guinea pigs [77, 78, 79].  
All species sequenced to date contain multiple trypsinogen genes in their genome, 
of which only a limited number are expressed at the protein level [80]. In humans, 9 
genomic trypsinogen sequences were identified, but only 3 isoforms are expressed to 
measurable protein levels [2]. The mouse genome contains 20 trypsinogen genes, but the 
resting mouse pancreas secretes only 4 trypsinogen isoforms (M. Sahin-Toth, unpublished 
data). The finding that the guinea pig pancreas secretes a single major isoform indicates 
that multiple isoforms are not an obligatory requirement for digestion, but they probably 
confer species-specific adaptive advantages. The guinea pig genome has not been 
sequenced yet, but it is very likely that it also contains multiple trypsinogen genes. This 
assumption is supported by the cloning of the 2 nearly identical cDNA forms, indicating 
the presence of at least 2 recently duplicated genes. 
 Although we posit that the guinea pig pancreas expresses 2 different mRNAs for 
pre-trypsinogen, which result in the expression of a single mature trypsinogen, there are 
caveats to this conclusion. First, the biochemical approach utilized here may not detect 
isoforms present in low quantities (1 % or less of total trypsinogens). Second, the cDNA 
cloning approach used may not identify isoforms in which the cDNA sequence around the 
catalytic Ser is less conserved, or isoforms present in very low amounts. Finally, hormonal 
stimulation of the pancreas may result in the expression of additional trypsinogen isoforms, 
which have not been found in this study. 
 Autoactivation of trypsinogen is believed to facilitate physiological zymogen 
activation in the duodenum. During autoactivation trypsin activates trypsinogen to trypsin, 
resulting in a self-amplifying reaction. Mutations in the human cationic trypsinogen that 
cause acceleration of autoactivation in vitro have been associated with hereditary 
pancreatitis, suggesting that autoactivation may be important for premature trypsinogen 
activation during pancreatitis, at least in humans [81]. The inability of the guinea pig 
trypsinogen to autoactivate indicates that this mode of trypsinogen activation is not 
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universally required for digestion. Therefore, the strong tendency for autoactivation 
observed with the human trypsinogens may indicate a positive evolutionary selection. The 
relatively high abundance of surface exposed charged side chains (Glu, Asp, Lys, Arg) in 
the human trypsinogens and their absence in the guinea pig trypsinogen suggests that 
efficient autoactivation requires interactions associated with these strongly polar amino 
acids. 
 There have been only scarce reports on experimental pancreatitis models using the 
guinea pig and the role of premature trypsinogen activation in the onset of pancreatitis has 
not been studied in this species. Furthermore, the inability of guinea pig trypsinogen to 
undergo autoactivation suggests that this species might be more resistant to pancreatitis 
than humans, where increased autoactivation of cationic trypsinogen mutants has been 
linked to hereditary pancreatitis. 
 Research on the pathomechanism of chronic pancreatitis came from relatively 
recent studies investigating the genes encoding cationic trypsinogen (PRSS1), anionic 
trypsinogen (PRSS2), and the pancreatic secretory trypsin inhibitor (SPINK1). Gain-of-
function variants in cationic trypsinogen have been linked to autosomal dominant 
hereditary pancreatitis and subsequently also to idiopathic chronic pancreatitis [28, 82, 83, 
84]. Recently, triplication of the locus of cationic trypsinogen has been observed in a 
subset of families with hereditary pancreatitis [85]. In vitro biochemical studies revealed 
that the majority of disease predisposing cationic trypsinogen variants increase 
autocatalytic conversion of trypsinogen to active trypsin and probably promote premature 
intrapancreatic trypsin activation in vivo [81, 86]. Consistent with the central 
pathophysiological role of trypsin, p.N34S and other loss-of-function alterations in the 
trypsin inhibitor SPINK1 predispose to idiopathic, tropical, and alcoholic chronic 
pancreatitis [87, 88, 89, 50, 90]. In contrast to pathogenic variations of cationic trypsinogen 
and pancreatic secretory trypsin inhibitor, the p.G191R variant of the anionic trypsinogen 
affords protection against chronic pancreatitis due to rapid autodegradation [32]. Taken 
together, genetic and biochemical evidence defines a pathological pathway in which a 
sustained imbalance between intrapancreatic trypsinogen activation and trypsin 
inactivation results in the development of chronic pancreatitis. It has been recently 
demonstrated that chymotrypsin C degrades all human trypsin and trypsinogen isoforms 
with high specificity and appears identical to enzyme Y, the enigmatic trypsinogen-
degrading activity described by Heinrich Rinderknecht in 1988 [16]. From these studies, 
chymotrypsin C emerged as a strong novel candidate for a pancreatitis-associated gene. 
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 Here we found that two alterations in the chymotrypsin gene (p.R254W and 
p.K247_R254del) were significantly overrepresented in all of the pancreatitis groups 
(idiopathic, hereditary chronic and alcoholic chronic types) compared to controls, in an 
extensive study, where more than 3700 individuals have been screened. This 
comprehensive mutation screening of the human chymotrypsin gene reveals the 
importance of a possible role of mutations in minor proteases in the initiation of 
pancreatitis. Furthermore, the investigations of functional consequences of the two 
chymotrypsin C variants, which showed decreased secretion (R254W) or totally 
diminished secretion and protease activity (R254del) strengthened our hypothesis about the 
role of loss-of-function mutations in trypsin-degrading enzymes in increasing the risk for 
pancreatitis (Fig 17). In summary, the genetic and functional data presented here identify 
chymotrypsin C as a novel pancreatitis associated gene. Our observations provide further 
support for the trypsin-dependent pathogenic model of chronic pancreatitis in humans by 
demonstrating that trypsin/trypsinogen degradation by chymotrysin C is an important 
mechanism in the maintenance of the physiological protease-antiprotease balance in the 
pancreas (Fig 17). These results (while this Nature Genetics paper appeared in print in the 
 
Figure 17. The trypsin dependent pathological model of chronic pancreatitis. Pancreatic defense mechanisms against 
unwanted trypsin activity include trypsin inhibition by SPINK1 (pancreatic secretory trypsin inhibitor) and trypsin 
degradation by CTRC. PRSS1 (cationic trypsinogen) missense variants stimulate activation of trypsinogen to trypsin or 
block degradation of active trypsin, whereas SPINK1 alterations reduce inhibitor levels and thus compromise trypsin 
inhibition. CTRC variations abolish activity or decrease secretion of CTRC and thereby impair trypsin degradation. 
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first issue of 2008)  have just been confirmed by another study of the human chymotrypsin 
C, which came out from an independent research group in a lesser journal [91], during the 
writing of this thesis.  
The next challenge was to identify whether bile acids and/or trypsin (e.g. during 
bile-induced acute pancreatitis) can trigger calcium signalling in guinea pig pancreatic 
ducts, if so, than we planned to determine the intracellular mechanisms by which 
chenodeoxycholate stimulates calcium signals. Bile acids induce an elevation in [Ca2+]i in 
various cell types including pneumocytes [92], hepatocytes [93], colonocytes [94] gastric 
mucosal cells [95], vascular endothelial cells [96] and importantly pancreatic acinar cells 
[35]. The fact that taurodeoxycholic acid-induced DIDS sensitive 125I- efflux can be 
inhibited by BAPTA-AM in dog pancreatic duct epithelial cells suggests that bile acids 
may induce Ca2+ signalling in these cells [97]. In our study we showed, for the first time, 
that both unconjugated and conjugated bile acids induce a dose-dependent elevation of 
[Ca2+]i in guinea pig pancreatic ductal epithelial cells. The unconjugated 
chenodeoxycholate had significantly larger effects than the conjugated 
glycochenodeoxycholate. Notably, the effect of luminal administration of a low dose of 
glycochenodeoxycholate was almost undetectable. We also showed that the Ca2+ signal 
induced by luminal administration of low doses of chenodeoxycholate was totally blocked 
by the calcium chelator BAPTA-AM, caffeine, the IP3 receptor inhibitor xestospongin C 
and the phospholipase C (PLC) inhibitor U73122, but unaffected by removal of 
extracellular Ca2+. The above mentioned inhibitors also had a similar effect on the [Ca2+]i 
elevation evoked by basolateral administration of a high dose of chenodeoxycholate. 
PAR-2 has been shown to be expressed in the pancreas [43, 44, 45], therefore, it is 
possible that activated trypsin (either by autoactivation or as a consequence of the lack of 
trypsin inhibitor or the trypsin-degrading chymotrypsin C) cleaves PAR-2 and stimulates  
cellular responses. In our experiments trypsin evoked calcium signalling in pancreatic duct 
epithelial cells, which proved to be specific responses as PAR-2 activating peptide 
triggered the same stimulatory effect and the signal could be blocked by a trypsin inhibitor. 
Trypsin mobilized almost exclusively intracellular calcium stores. PAR-2 expression was 
also detected by immunostaining of the guinea pig pancreas on the luminal membrane of 
intralobular ducts. In summary, during pathological conditions, trypsin and bile acids can 
activate pancreatic ductal epithelial cells through intracellular calcium signalling 
mechanisms and the activated cells might play an important role during the inflammation 
of the pancreatic tissue. 
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7. ANNEX 
 
SUPPLEMENTARY METHODS OF MUTATION SCREENING IN THE HUMAN 
CHYMOTRYPSINOGEN GENE. 
We designed primers complementary to intronic sequences flanking exons 1-8 of CTRC 
based on the published nucleotide sequence (GenBank # NT_004873). The annealing 
temperatures (Tann) used in the PCR reactions are also indicated in the Table below.  
Oligonucleotides used for PCR amplification and sequencing of CTRC (Berlin) 
PCR primers 
 Tann 
promoter region and exon 1 forward: 5´-CTCATCTCACCTCAGAGCAG-3´ 64°C 
 reverse: 5´-TAATCTGGGAAAACGCCACC-3´  
exons 2-3 forward: 5´-ACAGGTGTACCGGGCACTCG-3´ 64°C 
 reverse: 5´-TCACTGCTGGTTCCTGGCAC-3´  
exons 4-5 forward: 5´-CAAGGGCGGTGGAAGCTTGG-3´ 64°C 
 reverse: 5´-ATACCACAGATGTCATCCCC-3´  
exon 6 forward: 5´-TGACCCTCTGGGACCTTGGC-3´ 64°C 
 reverse: 5´-TGTGGGTTGGCTTCTCAGCC-3´  
exons 7-8 forward: 5´-GCTAGTCTGACACCCCAGGG-3´ 64°C 
 reverse: 5´-GCAGCTTGTGAGATGGAGCG-3´  
Sequencing primers 
  
promoter region  forward: 5´-GGCTGAGACAGGAGAATCGC-3´ 56°C  
exon 1 forward: 5´-GTAACCACCCAAGGTCAGGG-3´ 56°C 
exons 2-3 forward: 5´-GCCCAGCCCCAACTCTGTGC-3´ 56°C  
exon 4 forward: 5´-GCTACACAGCCAGGAGCAGC-3´ 56°C  
exon 5 forward: 5´-TCCACTCTCACCTCCCTCTG-3´ 56°C  
exon 6 forward: 5´-ATCTGCTCCCTGAAGGCCTG-3´ 56°C  
exon 7 forward: 5´-CCCTCACCATGGGCAGGCTG-3´ 56°C  
exon 7 reverse: 5´-GTGAATGAGTGAGGGGATGG-3´ 56°C 
exon 8 forward: 5´-CTGAGGGTATGGCCCAGCAG-3´ 56°C  
 
Oligonucleotides used for PCR amplification and sequencing of CTRC (Leipzig) 
PCR primers 
 Tann 
promoter region and exon 1 forward: 5´-CTCATCTCACCTCAGAGCAG-3´ 62°C 
 reverse: 5´-CTGGTTGGTAGCATCTGAAC-3´  
exons 2-3 forward: 5´-CTTTCCCCGTGGGCTACCA-3´ 62°C 
 reverse: 5´-GAAGCTGCTCAGAAAAAGCAGAGTA-3´  
exons 4-5 forward: 5´-GGAACTGAGGCACAAGGCTAC-3´ 62°C  
 reverse: 5´-TAGAGTGTCTGTCACATGGT-3´  
exon 6 forward: 5´-CAGCCTGAGCAACAGAGTGA-3´ 62°C 
 reverse: 5´-CAGTGAAGCCTCTTCTCTGT-3´  
exon 7 forward: 5´-GCCTCCCAGAATAAGGCCAAG-3´ 62°C 
 reverse: 5´-GCTACTGGAAGCACTCAACCA-3´  
exon 8 forward: 5´-GGACAAGGCTGGCATGTGA-3´ 60°C 
 reverse: 5´-GGCTCACTAAACACTTCTCA-3´  
Sequencing primers 
  
promoter region and exon 1 reverse: 5´-CTGGTTGGTAGCATCTGAAC-3´ 62°C  
exons 2-3 forward: 5´-GTGGGCTACCAGCCCTATTCA-3´ 62°C  
exon 4 reverse: 5´-GCCTTCCTTGTGGACTTTCCT-3´ 64°C  
exon 5 forward: 5´-TCCACTCTCACCTCCCTCTG-3´ 62°C  
exon 6 forward: 5´-TGACCCTCTGGGACCTTGGC-3´ 62°C  
exon 7 forward: 5´-GCTAGTCTGACACCCCAGGG-3´ 62°C  
exon 8 forward: 5´-AACTGGCTGAGTGGGGTCTC-3´ 62°C  
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After PCR amplification, the entire coding region and the exon-intron transitions were 
sequenced. In all patients analyzed in Berlin, both strands of exon 7 were sequenced. All 
mutations were confirmed with a second independent PCR reaction. PCR reactions were 
performed using slightly different conditions at the two centers. In Leipzig, 0.75 U 
AmpliTaq Gold polymerase (Applied Biosystems), 450 µmol/L deoxynucleoside 
triphosphates, and 0.3 µmol/L of each primer were used in a total volume of 25 µL. In 
Berlin, 0.5 U AmpliTaq Gold polymerase, 400 µmol/L deoxynucleoside triphosphates and 
0.1 µmol/L primers were used. Cycle conditions were as follows: initial denaturation for 6 
min at 95°C; 40 cycles of 20 s denaturation at 95°C, 40 s annealing (see temperatures in 
Table above) and 90 s primer extension at 72°C; and a final extension step for 6 min at 
72°C. In Berlin, 12 min initial denaturation and 2 min final extension was used. PCR 
products were digested with shrimp alkaline phosphatase (USB) and exonuclease I (USB). 
Cycle sequencing was performed using BigDye terminator mix (Applied Biosystems). The 
reaction products were purified with ethanol precipitation or on a Sephadex G-50 column 
(Amersham) and loaded onto an ABI 3100-Avant or an ABI 3730 fluorescence sequencer 
(Applied Biosystems). 
 
 
